{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:33Z","timestamp":1790931333902,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08049-0","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:57:50Z","timestamp":1783753070000},"page":"7049-7058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["68Ga-PSMA PET\/CT in biochemically recurrent prostate cancer: association with genomic data"],"prefix":"10.1007","volume":"53","author":[{"given":"Doris","family":"Leithner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Bedmutha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"A. Razmaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson W.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"8049_CR1","doi-asserted-by":"crossref","unstructured":"1. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666\u201377.","DOI":"10.1016\/j.cell.2013.03.021"},{"key":"8049_CR2","doi-asserted-by":"crossref","unstructured":"2. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017:1\u201316.","DOI":"10.1200\/PO.17.00029"},{"key":"8049_CR3","doi-asserted-by":"crossref","unstructured":"3. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Tilki D, van den Bergh RCN, Briers E, et al. Eur Urol. 2024;86:164\u2009\u2212\u200982.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"8049_CR4","doi-asserted-by":"crossref","unstructured":"4. Farolfi A, Ceci F, Castellucci P, et al. 68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA\u2009<\u20090.5 ng\/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. 2019;46:11\u20139.","DOI":"10.1007\/s00259-018-4066-4"},{"key":"8049_CR5","doi-asserted-by":"crossref","unstructured":"5. Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363.","DOI":"10.1001\/jamaoncol.2019.0096"},{"key":"8049_CR6","doi-asserted-by":"crossref","unstructured":"6. Calais J, Fendler WP, Eiber M, et al. Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59:434\u201341.","DOI":"10.2967\/jnumed.117.202945"},{"key":"8049_CR7","doi-asserted-by":"crossref","unstructured":"7. Metser U, Zukotynski K, Mak V, et al. Effect of 18F-DCFPyL PET\/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology. 2022;303:414\u201322.","DOI":"10.1148\/radiol.211824"},{"key":"8049_CR8","doi-asserted-by":"crossref","unstructured":"8. Pozdnyakov A, Kulanthaivelu R, Baumann G, et al. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer. A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:240-8.","DOI":"10.1038\/s41391-022-00544-3"},{"key":"8049_CR9","doi-asserted-by":"crossref","unstructured":"9. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomized, multicenter study. Lancet. 2020;395:1208-16.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"8049_CR10","doi-asserted-by":"crossref","unstructured":"10. Belliveau C, Saad F, Duplan D, et al. Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2025;11:1431-38.","DOI":"10.1001\/jamaoncol.2025.3746"},{"key":"8049_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239\u201343.","journal-title":"Nature"},{"key":"8049_CR12","doi-asserted-by":"crossref","unstructured":"12. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63:920\u20136.","DOI":"10.1016\/j.eururo.2012.08.053"},{"key":"8049_CR13","doi-asserted-by":"crossref","unstructured":"13. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697\u20131708.","DOI":"10.1056\/NEJMoa1506859"},{"key":"8049_CR14","doi-asserted-by":"crossref","unstructured":"14. Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378.","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"8049_CR15","doi-asserted-by":"crossref","unstructured":"15. Boutros PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localised, multifocal prostate cancer. Nat Gen. 2015;47:736\u201345.","DOI":"10.1038\/ng.3315"},{"key":"8049_CR16","doi-asserted-by":"crossref","unstructured":"16. Fendler WP, Eiber M, Beheshti M, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466-86.","DOI":"10.1007\/s00259-022-06089-w"},{"key":"8049_CR17","doi-asserted-by":"crossref","unstructured":"17. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT. J NUcl Med. 2018;59:469\u201378.","DOI":"10.2967\/jnumed.117.198119"},{"key":"8049_CR18","doi-asserted-by":"crossref","unstructured":"18. Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015;20:1422\u20138.","DOI":"10.1016\/j.drudis.2015.08.005"},{"key":"8049_CR19","doi-asserted-by":"crossref","unstructured":"19. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17:251\u201364.","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"8049_CR20","doi-asserted-by":"crossref","unstructured":"20. Weber WA, Czernin J, Anderson CJ, et al. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J Nucl Med. 2020;61:263S-272S.","DOI":"10.2967\/jnumed.120.254532"},{"key":"8049_CR21","doi-asserted-by":"crossref","unstructured":"21. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77:403\u201317.","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"8049_CR22","doi-asserted-by":"crossref","unstructured":"22. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60:786\u201393.","DOI":"10.2967\/jnumed.118.219501"},{"key":"8049_CR23","doi-asserted-by":"crossref","unstructured":"23. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258\u201368.","DOI":"10.1007\/s00259-017-3711-7"},{"key":"8049_CR24","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"JM Morris","year":"2021","unstructured":"Morris JM, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674\u201382.","journal-title":"Clin Cancer Res"},{"key":"8049_CR25","doi-asserted-by":"crossref","unstructured":"25. Chavoshi M, Mirshahvalad SA, Metser U, Veit-Haibach P. 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement. Eur J Nucl Med Mol Imaging. 2022;49:1021\u20139.","DOI":"10.1007\/s00259-021-05616-5"},{"key":"8049_CR26","doi-asserted-by":"crossref","unstructured":"26. Tan N, Bavadian N, Calais J, et al. Imaging of PSMA-targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. J Urol. 2019;202:231\u201340.","DOI":"10.1097\/JU.0000000000000198"},{"key":"8049_CR27","doi-asserted-by":"crossref","unstructured":"27. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453\u20136.","DOI":"10.1038\/351453a0"},{"key":"8049_CR28","doi-asserted-by":"crossref","unstructured":"28. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Instl. 1993;85:1657\u20139.","DOI":"10.1093\/jnci\/85.20.1657"},{"key":"8049_CR29","doi-asserted-by":"crossref","unstructured":"29. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"8049_CR30","doi-asserted-by":"crossref","unstructured":"30. Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","DOI":"10.1016\/j.cell.2015.10.025"},{"key":"8049_CR31","doi-asserted-by":"crossref","unstructured":"31. Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130:1743\u201351.","DOI":"10.1172\/JCI132031"},{"key":"8049_CR32","doi-asserted-by":"crossref","unstructured":"32. Hamid AA, Gray KP, Shaw G, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumour suppressors in localised and metastatic prostate cancer. Eur Urol. 2019;76:89\u201397.","DOI":"10.1016\/j.eururo.2018.11.045"},{"key":"8049_CR33","doi-asserted-by":"crossref","unstructured":"33. Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84\u20138.","DOI":"10.1126\/science.aah4307"},{"key":"8049_CR34","doi-asserted-by":"crossref","unstructured":"34. De Laere B, Oeyen S, Mayrhofer M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:1766\u201373.","DOI":"10.1158\/1078-0432.CCR-18-1943"},{"key":"8049_CR35","doi-asserted-by":"crossref","unstructured":"35. Liu C, Zhu Y, Lou W, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013;73:418\u201327.","DOI":"10.1002\/pros.22583"},{"key":"8049_CR36","doi-asserted-by":"crossref","unstructured":"36. Dong S, Yanmei L, Chen, J, et al. 18F-PSMA-1007 PET\/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer. Front Oncol. 2022, 12:1025930.","DOI":"10.3389\/fonc.2022.1025930"},{"key":"8049_CR37","doi-asserted-by":"crossref","unstructured":"37. Hong MK, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015;6:6605.","DOI":"10.1038\/ncomms7605"},{"key":"8049_CR38","doi-asserted-by":"crossref","unstructured":"38. Sheehan B, Guo C, Need A, et al. Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 2022;8:1157\u201368.","DOI":"10.1016\/j.euf.2021.06.006"},{"key":"8049_CR39","doi-asserted-by":"crossref","unstructured":"39. Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13\u201330.","DOI":"10.1038\/nrclinonc.2017.151"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08049-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:01Z","timestamp":1790929921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8049"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08049-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Memorial Sloan Kettering Cancer Center.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived given the retrospective design of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}